- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature
© Amzerin et al; licensee BioMed Central Ltd. 2011
Received: 11 December 2010
Accepted: 3 October 2011
Published: 3 October 2011
Ameloblastoma is a rare benign odontogenic tumor with locally aggressive behavior and a high recurrence rate. When metastases occur, which are uncommon, lungs constitute the most frequent site involved. Malignant ameloblastomas are different from ameloblastic carcinomas. Malignant ameloblastomas are tumors considered metastatic despite the appearance of well-differentiated or benign histology, while ameloblastic carcinomas are histologically malignant in both primary and metastatic sites.
A 24-year-old Moroccan man presented a malignant ameloblastoma of the mandible. The tumor was entirely resected. Five years later, a local recurrence occurred. Our patient was treated by exclusive radiotherapy with persistence of a residual disease. After two years he developed multiple lung metastases. Our patient received a combination chemotherapy using doxorubicin and cisplatin.
Less than 50 cases of ameloblastoma with metastases have been reported. There is still no standard treatment for metastatic ameloblastoma. Only through continuous reporting of such cases will clinicians be able to draw an optimal strategy for management of this pathology.
Ameloblastoma, from the English word "amel" which means enamel and the Greek word "blastos" which means germ , is a rare entity of benign odontogenic tumor. It arises from the epithelium of the dental lamina and it is known by its local aggressive behavior and the high recurrence rate .
Ameloblastoma was first described in 1827 by Cusack . In 1885, Malassez introduced the name "adamantinoma", which is now used to describe a rare form of bone cancer described by Fisher in 1913 . It was renamed to its current denomination by Churchill in 1930 .
In the recent WHO classification, a distinction was made between ameloblastoma, malignant ameloblastoma and ameloblastic carcinoma . Malignant ameloblastoma differs from ameloblastoma due to the presence of metastases. They both have the same benign histology . Ameloblastic carcinoma has malignant cytologic features regardless of the presence of metastases. In ameloblastoma, metastases are uncommon. When they occur, lungs are involved in over 80% of cases .
Localized disease is treated by radical surgery. However, in metastatic settings, chemotherapy remains the only choice of treatment. Unfortunately, results are unpredictable. We report below a case of an ameloblastoma with metastatic evolution five years after initial surgical treatment.
Odontogenic neoplasms are rare tumors of the oral cavity. Among these, ameloblastoma is the second most common entity after odontoma . Ameloblastoma and metastatic ameloblastoma are different. According to the recent WHO classification, ameloblastoma is a localized benign disease whereas malignant ameloblastoma is considered metastatic despite the appearance of well differentiated or benign histology. Ameloblastic carcinoma shows malignant features in both primary and metastatic sites .
The average age at diagnosis of patients with ameloblastoma is 34 years with a range of five to 74 years . Men and women are equally affected. The most frequent primary site is the angle of the mandible.
There are several histological subtypes, including plexiform, follicular, acanthomatous, basaloid, granular cell, cystic and desmoplastic forms. So far, the natural course of the disease can not be predicted. The follicular entity is the most common . Basic symptoms are a swelling mass, pain and fistula in the palate .
Ameloblastoma is described as a slowly growing, locally invasive benign tumor with a high propensity for local recurrence. There is a 50% to 72% incidence of local recurrence after initial therapy . Radical surgery remains the mainstay of therapy. This is often difficult because of the anatomical complexity of the mandibular region. In case of incomplete resection, radiotherapy can be considered as an adjuvant measure.
Metastases are uncommon, which is why metastatic ameloblastoma is considered benign (in addition to the benign features on histology). They generally occur after an interval ranging from 10 to 12 years . Lungs are involved in 75% to 80% of cases. Other sites may also be involved, such as regional lymph nodes, pleura, vertebra, skull, diaphragm, liver and parotid glands . Many factors have been associated with the tendency to develop metastases, including extent of initial disease, multiple surgeries or radiation therapy [6–8]. Several theories have been suggested to explain metastatic spread, relating to lymphatic or hematogenous causes, aspiration or heterotopia .
Published data concerning chemotherapy regimens used in metastatic ameloblastoma
Partial response: 50%
-W, 17 years old
1st line: 5FU-Cisplatin
Progression disease after two cycles; repetitive partial response.
-W, 28 years old
2nd line: Paclitaxel-
-M, 46 years old
-Lung metastases + mediastinal adenopathies
Stable disease during 18 months
-M, 55 years old
No chemotherapy; surgery for removable metastases.
Survival: 54 years
-W, 39 years old
Doxorubicin ± 5FU.
Outcome of chemotherapy in metastatic ameloblastoma.
Methotrexate ± cyclophosphamide
A review of the literature made by Lanham concluded that chemotherapy failed to show any antitumoral activity, including doxorubicin, methotrexate, prednisolone, bleomycin, 5-fluorouracil and dacarbazin . Moreover, the literature reports some patients with metastases showing long survival without receiving chemotherapy [6, 15].
Our case illustrates the natural course of the disease. In spite of radical surgery, lesions recurred. The metastases were asymptomatic. They were discovered during a classical work-up. Our finding, concerning response to doxorubicin-cisplatin, is adding to the published evidence that platinum chemotherapy is active in metastatic ameloblastoma. Moreover, even though no objective response is seen, data show that chemotherapy improves clinical symptoms .
There are too few cases of metastatic ameloblastoma to consider randomized trials. Platinum-based regimens could be proposed as a first line treatment. Another pathway to explore is epidermal growth factor receptor (EGFR)-targeting. Ameloblastoma is a tumor originating from EGFR-expressing odontogenic epithelium, with expression levels ranging from 0% to 100% in some studies .
Despite the slowly growing nature of ameloblastoma, endocranial extension and/or occurrence of metastases cause pain and affect survival.
In metastatic ameloblastoma, results are unpredictable. Surgery, when feasible, remains the mainstay of therapy. There is no sufficient data to support or reject the use of chemotherapy. The expression of EGFR by odontogenic tumors could be an interesting approach to explore.
Written informed consent was obtained from our patient for publication of this case report and any accompanying images.
We are indebted to Prof Errihani, Prof Kebdani, Prof Hassouni, Prof Benjaafar, Prof Gueddari, Dr Boutayeb and Dr M'Rabti for their assistance in preparation and interpretation of the pathological findings.
- Brazis PW, Miller NR, Lee AG, Holliday MJ: Neuro-ophthalmologic aspects of ameloblastoma. Skull Base Surg. 1995, 5 (4): 233-244. 10.1055/s-2008-1058921.View ArticlePubMedPubMed CentralGoogle Scholar
- Jordan RCK, Speight PM: Current concepts of odontogenic tumours. Diagn Histopathol. 2009, 15 (6): 303-310. 10.1016/j.mpdhp.2009.03.002.View ArticleGoogle Scholar
- Cusack JW: Report of the amputations of the lower jaw. Dublin Hosp Rec. 1827, 4: 1-38.Google Scholar
- Malassez L: Sur Le role des debris epitheliaux papdentaires. Arch Physiol Norm Pathol. 1885, 5: 309-340. 6:379-449Google Scholar
- Ivery RH, Churchill L: The need of a standardized surgical and pathological classification of tumors and anomalies of dental origin. Am Assoc Dent Sch Trans. 1930, 7: 240-245.Google Scholar
- Ciment LM, Ciment AJ: Malignant ameloblastoma metastatic to the lungs 29 years after primary resection. Chest. 2002, 121: 1359-1361. 10.1378/chest.121.4.1359.View ArticlePubMedGoogle Scholar
- Henderson JM, Sonnet JR, Schlesinger C, Ord RA: Pulmonary metastasis of ameloblastoma: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999, 88 (2): 170-176. 10.1016/S1079-2104(99)70113-7.View ArticlePubMedGoogle Scholar
- Gilijamse M, Leemans CR, Winters HA, Schulten EA, van der Waal I: Metastasizing ameloblastoma. Int J Oral Maxillofac Surg. 2007, 36 (5): 462-464. 10.1016/j.ijom.2006.12.005.View ArticlePubMedGoogle Scholar
- Grünwald V, Le Blanc S, Karstens JH, Weihkopf T, Kuske M, Ganser A, Schöffski P: Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin. Ann Oncol. 2001, 12 (10): 1489-1491. 10.1023/A:1012522929861.View ArticlePubMedGoogle Scholar
- Houston G, Davenport W, Keaton W, Harris S: Malignant ameloblastoma: report of a case. J Oral Maxillofac Surg. 1993, 51: 1152-1155. 10.1016/S0278-2391(10)80458-6. discussion 1156-1157View ArticlePubMedGoogle Scholar
- Gall JA, Sartiano GP, Shreiner DP: Ameloblastoma of the mandible with pulmonary metastasis. Oncology. 1975, 32 (3-4): 118-126. 10.1159/000225058.View ArticlePubMedGoogle Scholar
- Ramadas K, Jose CC, Subhashini J, Chandi SM, Viswanatham FR: Pulmonary metastases from ameloblastoma of the mandible teated with cisplatin, adriamycin and cyclophosphamid. Cancer. 1989, 66: 1475-1479.View ArticleGoogle Scholar
- Eliasson AH, Moser RJ, Tenholder MF: Diagnosis and treatment of metastatic ameloblastoma. South Med J. 1989, 82 (9): 1165-1168. 10.1097/00007611-198909000-00027.View ArticlePubMedGoogle Scholar
- Lanham RJ: Chemotherapy of metastatic ameloblastoma. A case report and review of the literature. Oncology. 1987, 44 (2): 133-134. 10.1159/000226461.View ArticlePubMedGoogle Scholar
- Hasim FW, Poon CC, Smith A: Prolonged survival with confirmed metastatic pulmonary ameloblastoma. Int J Oral Maxillofac Surg. 2007, 36 (10): 953-935. 10.1016/j.ijom.2007.02.010.View ArticlePubMedGoogle Scholar
- Vered M, Shohat I, Buchner A: Epidermal growth factor receptor expression in ameloblastoma. Oral Oncol. 2003, 39 (2): 138-143. 10.1016/S1368-8375(02)00034-9.View ArticlePubMedGoogle Scholar
- Campbell D, Jeffrey RR, Wallis F, Hulks G, Kerr KM: Metastatic pulmonary ameloblastoma: an unusual case. Br J Oral Maxillofac Surg. 2003, 41 (3): 194-196. 10.1016/S0266-4356(03)00046-9.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.